...
首页> 外文期刊>Therapeutic Drug Monitoring >Developing a nomogram for dose individualization of phenytoin in asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug
【24h】

Developing a nomogram for dose individualization of phenytoin in asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug

机译:从人群的药代动力学模型对药物的饱和药代动力学特征进行推导,开发出亚洲儿童患者苯妥英钠剂量个性化的列线图

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A population pharmacokinetic model for phenytoin in Asian pediatric patients was developed to determine the influence of concurrent medications, patient demographics, and blood biochemistry on the pharmacokinetic profile of phenytoin. METHODS: Retrospective clinical data were obtained from 66 patients (age, 1-16 years) for the determination of pharmacokinetic parameters of phenytoin using WinNonmix. Data from 49 patients (74.2%) were allocated in the "index" group, and the other 17 patients (25.8%) in the "validation" group. Models were compared by final log likelihood, mean error as a measure of bias, and root-mean-squared error as a measure of precision. RESULTS: The Michaelis-Menten constant (km) and volume of distribution (V) were fixed at 9.08 mg/L and 1.23 L/kg, respectively. The saturated elimination rate (V × Vmax) of phenytoin was then found to be 0.525 mg/kg per hour (352.9 4 mg/d for a 28.0 kg individual). Patients' body surface area (in square meter) and catalytic activities of liver enzymes aspartate aminotransferase (U/L) and alkaline phosphatase (U/L) appeared to have significant correlation with Vmax, whereas coadministrating drugs with phenytoin did not yield any significant effect. The final model for the saturated elimination rate was(Equation is included in full-text article.)In validation of the final model, the mean error was found to be -0.805 (95% confidence interval, -3.67 to 2.06), and the root-mean-squared error was 7.92 (95% confidence interval, 3.41-12.43). CONCLUSIONS: The obtained results indicated the need to consider patients' body surface area and the catalytic activities of liver enzymes aspartate aminotransferase and alkaline phosphatase when dosing phenytoin. Based on the population pharmacokinetic parameters, a nomogram was subsequently developed for dose individualization of phenytoin in Asian pediatric patients.
机译:背景:开发了亚洲儿童患者苯妥英钠的总体药代动力学模型,以确定同时用药,患者人口统计学和血液生化对苯妥英钠药代动力学的影响。方法:回顾性临床资料来自66例患者(年龄1-16岁),用于使用WinNonmix测定苯妥英的药代动力学参数。 “索引”组分配了49位患者(74.2%)的数据,“验证”组分配了其他17位患者(25.8%)的数据。通过最终对数似然,平均误差(作为偏差的度量)和均方根误差(作为精度的度量)对模型进行比较。结果:米氏常数(kmis)和分布体积(V)分别固定为9.08 mg / L和1.23 L / kg。然后发现苯妥英钠的饱和消除速率(V×Vmax)为每小时0.525 mg / kg(对于28.0 kg的个体,为352.9 4 mg / d)。患者的体表面积(平方米)以及肝酶天冬氨酸转氨酶(U / L)和碱性磷酸酶(U / L)的催化活性似乎与Vmax显着相关,而与苯妥英钠合用的药物未产生任何显着影响。饱和消除率的最终模型为(方程包括在全文中。)在验证最终模型时,发现平均误差为-0.805(95%置信区间为-3.67至2.06),并且均方根误差为7.92(95%置信区间,3.41-12.43)。结论:获得的结果表明,在服用苯妥英钠时,需要考虑患者的体表面积以及肝酶天冬氨酸转氨酶和碱性磷酸酶的催化​​活性。根据人群的药代动力学参数,随后开发了诺模图,用于亚洲儿童患者的苯妥英钠剂量个性化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号